Disproquima, known for its comprehensive distribution of raw materials and ingredients across various sectors, has strategically expanded its portfolio and strengthened its position in the global market with the acquisition of Res Pharma.
The move reflects Disproquima's commitment to providing clients with an even broader range of innovative, sustainable and market-trend-focused solutions.
"We are thrilled to announce the acquisition of Res Pharma, a company that shares our commitment to excellence and innovation in the life science industry," said Jordi Sánchez, CEO at Disproquima.
"This strategic move allows us to enhance our capabilities and further support our clients with a comprehensive suite of products and services."
Res Pharma, with a rich history spanning 60 years, has been a key player in carefully selecting and providing top-tier ingredients to its clients. The company's dedication to offering 360° solutions, encompassing innovation, sustainability and current market trends, aligns seamlessly with Disproquima's values and vision for the future.
"This acquisition marks an exciting chapter for Res Pharma," stated Letizia Facchini, President at Res Pharma.
"Joining forces with Disproquima opens up new opportunities for us to continue delivering exceptional value to our customers. Together, we can leverage our strengths to create a more significant impact on the global life science industry."
The collaboration between Disproquima and Res Pharma will harness the collective expertise of both companies to provide clients with unparalleled sales and marketing advice, quality and regulatory support, efficient logistics and full transparency.
The union is poised to result in a robust synergy that will benefit clients across the pharma, dietary supplements, food & beverage, personal care and animal nutrition industries.
As Disproquima extends its reach across four continents, this acquisition demonstrates the company's commitment to fostering growth, innovatio and excellence in the life science industry.
